Dear Editor, A 21-year-old male patient affected by severe atopic dermatitis (AD) since
childhood started dupilumab in January 2019 after treatment failure with cyclosporin. Serum …

Discussion AD is characterized by cutaneous and systemic type 2 inflammation with the
recruitment of Th2 cells, eosinophils, and dendritic cells to skin lesions. Although the …

DISCUSSION To achieve a targeted efficacy profile in patients with AD, biologic treatments
are projected to replace topical corticosteroids and systemic immunosuppressants. Since …

Dear Editor, During the global pandemic by the new severe acute respiratory syndrome-
coronavirus 2 (SARS-CoV-2), dupilumab has been preferred for treating severe atopic …

Atopic dermatitis (AD) is a common inflammatory cutaneous disease characterized by itchy
eczematous lesions and xerosis with a chronic or relapsing/remitting course that presents as …

A 36-year-old Caucasian female with a long history of atopic dermatitis presented with
multiple flares eventually leading to dupilumab therapy. Five months into the dupilumab …

We present the case of a 31-year-old Caucasian woman, who came to our clinic due to the
worsening of her previously diagnosed atopic eczema, initially localized on her hands but …

To the Editor: We read with interest the article by Tracey et al 1 reporting on the
erythrodermic presentation of psoriasis in a patient treated with dupilumab. This Case …

Dear Editor, Dupilumab is a human monoclonal antibody that inhibits the signaling of
interleukin (IL)-4 and IL-13, which are key inflammatory cytokines of atopic dermatitis (AD) …

Discussion We report a temporal relationship between dupilumab and the subsequent
development of AA. Of course, temporal cannot be interpreted as causal; however, we …